Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Skin Neoplasms 2Lymphoma 2Melanoma 1Lymphoma, T-Cell 1Kidney Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 23aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Biopsy 7dabrafenib 6Surveys and Questionnaires 6Dacarbazine 6trametinib 5binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Blood Specimen Collection 5Aminolevulinic Acid 5sonidegib 4encorafenib 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Educational Status 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Skin Neoplasms × zanolimumab × Clear all
NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
22 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡